Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.

Abstract

PURPOSE This phase II trial evaluated the safety and efficacy of yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma (MCL). PATIENTS AND METHODS Patients with relapsed or refractory MCL were eligible for the study if they had adequate major organ function and performance status. Those with CNS disease… (More)
DOI: 10.1200/JCO.2009.21.8545

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.